Birch Pollen Allergy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Birch Pollen Allergy - Pipeline Review, H2 2016

Birch Pollen Allergy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Birch Pollen Allergy - Pipeline Review, H2 2016
Published Jul 20, 2016
49 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Birch Pollen Allergy - Pipeline Review, H2 2016, provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
- The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline

  
Source:
Document ID
GMDHC8255IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Birch Pollen Allergy Overview61
Therapeutics Development71
  Pipeline Products for Birch Pollen Allergy Overview71
Birch Pollen Allergy Therapeutics under Development by Companies81
Birch Pollen Allergy Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
Birch Pollen Allergy Products under Development by Companies121
Birch Pollen Allergy Companies Involved in Therapeutics Development137
  ALK-Abello A/S131
  Allergopharma GmbH &Co. KG141
  Anergis SA151
  Biomay AG161
  Circassia Pharmaceuticals Plc171
  HAL Allergy BV181
  Stallergenes SAS191
Birch Pollen Allergy Therapeutics Assessment206
  Assessment by Monotherapy Products201
  Assessment by Target211
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Drug Profiles2611
  Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile261
  Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis Drug Profile271
  AllerT Drug Profile284
  Birch Pollen Allergoid Drug Profile321
  BM-31 Drug Profile331
  PL-102 Drug Profile341
  STG-210 Drug Profile351
  Vaccine for Birch Pollen Allergy Drug Profile361
Birch Pollen Allergy Dormant Projects371
Birch Pollen Allergy Discontinued Products381
Birch Pollen Allergy Product Development Milestones399
  Featured News &Press Releases391
    Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016391
    Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial401
    Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen401
    Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting411
    Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT411
    Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT421
    May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen421
    Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT431
    Feb 27, 2014: Phase IIb Results of Anergis Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego431
    Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT441
    Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT441
    Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT451
    Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment451
    Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen461
    Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US462
Appendix482
  Methodology481
  Coverage481
  Secondary Research481
  Primary Research481
  Expert Panel Validation481
  Contact Us481
  Disclaimer491

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Birch Pollen Allergy - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Birch-Pollen-Allergy-Pipeline-Review-H2-2016-2088-16229>
  
APA:
Global Markets Direct - Market Research. (2016). Birch Pollen Allergy - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Birch-Pollen-Allergy-Pipeline-Review-H2-2016-2088-16229>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.